On 25 August, Jointown Pharmaceutical Group Co., Ltd. received credit rating results for the Company's corporate credit status from credit rating agency China Chengxin International Credit Rating Co., Ltd., which assigned the Company a corporate credit rating of AAA with a "stable" outlook. This rating upgrade signifies that Jointown's comprehensive strength has gained high recognition from both the industry and capital markets, making it the only private enterprise in the pharmaceutical circula

On 17 September 2025, Jointown Pharmaceutical Group Co., Ltd. successfully passed the acceptance inspection organized by the National Archives Administration for its "Enterprise Group Digital Archives Construction Pilot" project, becoming the only private enterprise in Hubei Province to participate in and pass the project's acceptance inspection. This milestone marks that the Group's archive digitization and standardization efforts have entered a new stage.

Recently, Jointown donated hemodialysis equipment and supplies worth RMB 1.31 million to grassroots community health service centers in Miyun District, Beijing, through the Beijing Red Cross Society. Efforts have been made to support post-disaster recovery and reconstruction, strengthen primary healthcare services, and contribute to the development of the grassroots medical security system through concrete actions.

On 27 August, Jointown disclosed its 2025 semi-annual report, showing that the Company achieved operating revenue of RMB 81.106 billion, a year-on-year increase of 5.10%; net profit attributable to the parent company reached RMB 1.446 billion, a year-on-year increase of 19.70%, achieving dual growth in both operating revenue and net profit attributable to the parent company.

Jointown stated that in the first half of 2025, amid overall industry growth pressure, the Company continued to focus on